By combining innovative prevention and treatment strategies in a sustainable state‐of‐the‐art virtual European cancer centre/infrastructure, it will be possible by 2030 to achieve a long‐term survival of 3 out of 4 cancer patients in countries with well‐developed healthcare systems.
Cancer Core Europe provides a great translational platform to bridge the gap from bench-to-bedside and bedside-to-bench, conducting next-generation clinical trials, and discovery of predictive biomarkers and markers to monitor resistance.
Effective treatment of cancer remains one of the biggest medical challenges in the world, due to the large diversity in the spectrum of mutations in individual cancer patients. To tackle this problem, cancer research will need to be performed at a larger scale than is currently possible within single cancer institutes.
“The development of Cancer Core Europe is exciting. The understanding of the science that drives cancer growth is leading to rapid and significant changes in how we need to approach the diagnosis, monitoring and treatment of patients with cancer. If we are to be successful in bringing revolutionary new treatment regimens to patients quickly it will require this kind of collaboration across cancer centres. AZ Oncology looks forward to also collaborating with Cancer Core Europe to help deliver this revolutionary vision."
“Our understanding of cancer is increasing faster than ever before, and over the next decade or so I believe that this will lead to a revolution in how physicians treat patients. This network will lead that revolution.”
Patrick Maxwell, Regius Professor of Physic and Head of the School of Clinical Medicine
Cancer is still the illness with the highest mortality rates in the world. Solving this problem requires new strategies, which is why a new European consortium is now being built – Cancer Core Europe – in which six of Europe's most prominent cancer research centres take part. Karolinska Institutet is one of them.